NO993841D0 - Blandinger og anordninger for redusering av virkningene av inflamasjon - Google Patents

Blandinger og anordninger for redusering av virkningene av inflamasjon

Info

Publication number
NO993841D0
NO993841D0 NO993841A NO993841A NO993841D0 NO 993841 D0 NO993841 D0 NO 993841D0 NO 993841 A NO993841 A NO 993841A NO 993841 A NO993841 A NO 993841A NO 993841 D0 NO993841 D0 NO 993841D0
Authority
NO
Norway
Prior art keywords
tissue
injured tissue
inflammation
photosensitizing agent
reducing
Prior art date
Application number
NO993841A
Other languages
English (en)
Other versions
NO993841L (no
NO327175B1 (no
Inventor
Anna M Richter
Julia G Levy
Claude A A Hariton
Gustave Huber
William C Stewart
Mario Giulio Fsadni
Original Assignee
Qlt Phototherapeutics Inc
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/942,883 external-priority patent/US6274614B1/en
Application filed by Qlt Phototherapeutics Inc, Univ British Columbia filed Critical Qlt Phototherapeutics Inc
Publication of NO993841D0 publication Critical patent/NO993841D0/no
Publication of NO993841L publication Critical patent/NO993841L/no
Publication of NO327175B1 publication Critical patent/NO327175B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19993841A 1997-02-11 1999-08-10 Anvendelse av fotosensibiliserende middel som er i stand til a penetrere vev, for fremstilling av et medikament for reduksjon eller forhindring av virkningene av inflammasjon som skriver seg fra skadet vev. NO327175B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79796397A 1997-02-11 1997-02-11
US08/942,883 US6274614B1 (en) 1997-02-11 1997-10-02 Methods, compositions and articles for reducing or preventing the effects of inflammation
PCT/IB1998/000181 WO1998034644A1 (en) 1997-02-11 1998-01-14 Compositions and articles for reducing the effects of inflammation

Publications (3)

Publication Number Publication Date
NO993841D0 true NO993841D0 (no) 1999-08-10
NO993841L NO993841L (no) 1999-10-08
NO327175B1 NO327175B1 (no) 2009-05-04

Family

ID=27121943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993841A NO327175B1 (no) 1997-02-11 1999-08-10 Anvendelse av fotosensibiliserende middel som er i stand til a penetrere vev, for fremstilling av et medikament for reduksjon eller forhindring av virkningene av inflammasjon som skriver seg fra skadet vev.

Country Status (14)

Country Link
US (1) US6677366B2 (no)
EP (1) EP0996465B1 (no)
JP (2) JP4012575B2 (no)
CN (1) CN1187089C (no)
AT (1) ATE270114T1 (no)
AU (1) AU734366B2 (no)
CA (1) CA2279427C (no)
CZ (1) CZ295734B6 (no)
DE (1) DE69824853T2 (no)
ES (1) ES2224355T3 (no)
HK (1) HK1028190A1 (no)
NO (1) NO327175B1 (no)
NZ (1) NZ337077A (no)
WO (1) WO1998034644A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001258095A1 (en) 2000-05-08 2001-11-20 The University Of British Columbia Drug delivery systems for photodynamic therapy
US8106038B2 (en) 2001-02-15 2012-01-31 Qlt Inc. Method for reducing or preventing PDT related inflammation
NL1020336C2 (nl) * 2002-04-09 2003-10-13 Photobiochem Leiden N V Toepassing van een verbinding voor de bereiding van een farmaceutisch preparaat voor het behandelen van brandwonden, en een werkwijze voor het behandelen van brandwonden.
WO2006015016A2 (en) 2004-07-30 2006-02-09 Massachusetts Eye And Ear Infirmary Photodynamic therapy and compositions for treating ocular glaucoma
US7479136B2 (en) * 2005-04-14 2009-01-20 Dotson Robert S Ophthalmic phototherapy treatment method
US20060235493A1 (en) * 2005-04-14 2006-10-19 Dotson Robert S Ophthalmic phototherapy device and associated treatment method
US20130079759A1 (en) 2005-04-14 2013-03-28 Robert S. Dotson Ophthalmic Phototherapy Device and Associated Treatment Method
US20080269730A1 (en) 2005-04-14 2008-10-30 Dotson Robert S Ophthalmic Phototherapy Device and Associated Treatment Method
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
WO2015130944A1 (en) * 2014-02-28 2015-09-03 Massachusetts Eye & Ear Infirmary Methods for cross-linking corneal collagen with verteporfin for the treatment of disorders of the eye
WO2016040534A1 (en) 2014-09-09 2016-03-17 LumiThera, Inc. Multi-wavelength phototherapy devices, systems, and methods for the non-invasive treatment of damaged or diseased tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5283255A (en) 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
DE69221828T2 (de) 1991-06-21 1998-04-09 Baxter Int Verfahren zur inaktivierung von pathogenen in einer körperflüssigkeit
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
US5707986A (en) 1994-03-14 1998-01-13 Miller; Joan W. Angiographic method using green porphyrins in primate eyes
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye

Also Published As

Publication number Publication date
AU734366B2 (en) 2001-06-14
NO993841L (no) 1999-10-08
CZ282299A3 (cs) 2000-02-16
CA2279427A1 (en) 1998-08-13
ATE270114T1 (de) 2004-07-15
CN1269729A (zh) 2000-10-11
CZ295734B6 (cs) 2005-10-12
DE69824853D1 (de) 2004-08-05
NZ337077A (en) 2001-06-29
CN1187089C (zh) 2005-02-02
JP2005272464A (ja) 2005-10-06
JP2002509531A (ja) 2002-03-26
DE69824853T2 (de) 2006-01-12
HK1028190A1 (en) 2001-02-09
NO327175B1 (no) 2009-05-04
CA2279427C (en) 2009-11-24
US20020103180A1 (en) 2002-08-01
EP0996465B1 (en) 2004-06-30
WO1998034644A1 (en) 1998-08-13
ES2224355T3 (es) 2005-03-01
EP0996465A1 (en) 2000-05-03
AU5777298A (en) 1998-08-26
JP4012575B2 (ja) 2007-11-21
US6677366B2 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ATE153853T1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
SE8503680L (sv) Indolderivat
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE69804281T2 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Leberkrankheiten
NO993841D0 (no) Blandinger og anordninger for redusering av virkningene av inflamasjon
DE69840911D1 (de) Gelierte zusammensetzungen
ES2171933T3 (es) Derivados de androsteno.
HK1022091A1 (en) Percutaneous absorption type preparation
NO954878L (no) Pyrrolderivater
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
EP1120119A4 (en) REMEDIES FOR PHOTOCHEMOTHERAPY
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DE69941629D1 (de) Durchsichtige transdermale nicotinabgabevorrichtungen
NO20012817D0 (no) Phenethyl-5-bromopyridylthiourea (PBT) og dihydroalkoxybenzyloxopyrimidine (DABO) derivater som utöverspermicidal aktivitet
SE8600496L (sv) Farmaceutiska kompositioner innehallande 9,10-dihydroergotalkaloider
AU8355598A (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in phot odynamictherapy and certain such novel derivatives
WO2000038620A3 (en) A composition useful to treat periodontal disease
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
ES2062125T3 (es) Una composicion farmaceutica que contiene derivados de hidantoina.
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA, CA

MK1K Patent expired